Breast cancer genes: Beyond BRCA1 and BRCA2

Frontiers in Bioscience

Volumn 18, Issue 4, 2013, Pages 1358-1372

  Filippini, Sandra E ^a,b   Vega, Ana ^c  

^a Genetic Unit   (Spain)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

BRCA1; BRCA2; Breast cancer genes; Fanconi anemia genes; Genetic diagnosis; Hereditary breast ovarian cancer syndrome; Review

Indexed keywords

EID: 84880541734     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4185     Document Type: Article

References (100)

1. F Eisinger, H Sobol, D Serin and JC Whorton: Hereditary breast cancer, circa 1750. Lancet 351, 1366 (1998). (Pubitemid 28195936)
2. P Broca. Traité des Tumeurs. Paris: Asselin (1866).
3. JM Hall, MK Lee, B Newman, JE Morrow, LA Anderson, B Huey and MC King: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 1684-1689 (1990). (Pubitemid 120031871)
4. Y Miki, J Swensen, D Shattuck-Eidens, PA Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, LM Bennett and W Ding: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994). (Pubitemid 24345325)
5. R Wooster, SL Neuhausen, J Mangion, Y Quirk, D Ford, N Collins, K Nguyen, S Seal, T Tran and D Averill: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265, 2088-2090 (1994). (Pubitemid 24325690)
6. R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs and G Micklem: Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995). (Pubitemid 26004412)
7. P Smith, L McGuffog, DF Easton, GJ Mann, GM Pupo, B Newman, G Chenevix-Trench, kConFab Investigators, C Szabo, M Southey, H Renard, F Odefrey, H Lynch, D Stoppa-Lyonnet, F Couch, JL Hopper, GG Giles, MR McCredie, S Buys, I Andrulis, R Senie, B C G BCFS, DE Goldgar, R Oldenburg, K Kroeze-Jansema, J Kraan, H Meijers-Heijboer, JG Klijn, C van Asperen, I van Leeuwen, HF Vasen, CJ Cornelisse, P Devilee, L Baskcomb, S Seal, R Barfoot, J Mangion, A Hall, S Edkins, E Rapley, R Wooster, J Chang-Claude, D Eccles, DG Evans, PA Futreal, KL Nathanson, BL Weber, Breast Cancer Susceptibility Collaboration (UK), N Rahman and M RStratton: A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer. 45, 646-655 (2006).
8. TM Mack, AS Hamilton, F Press, A Diep and EB Rappaport: Heritable breast cancer in twins. Br J Cancer 87, 294-300 (2002).
9. AC Antoniou and DF Easton: Models of genetic susceptibility to breast cancer. Oncogene 25, 5898-5905 (2006). (Pubitemid 44453445)
10. K Gudmundsdottir and A Ashworth: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864-5874 (2006). (Pubitemid 44453442)
11. B Wang, BRCA1 tumor suppressor network: focusing on its tail. Cell Biosci 2, 6-3701-2-6 (2012).
12. C Moiola, P De Luca, J Cotignola, K Gardner, E Vazquez and A De Siervi: Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. Cell Physiol Biochem 30, 596-608 (2012).
13. A De Siervi, P De Luca, JS Byun, LJ Di, T Fufa, CM Haggerty, E Vazquez, C Moiola, DL Longo and K Gardner: Transcriptional autoregulation by BRCA1. Cancer Res 70, 532-542 (2010).
14. PJ O'Donovan and DM Livingston: BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31, 961-967 (2010).
15. WD Foulkes: Inherited susceptibility to common cancers. N Engl J Med 359(20):2143-53 (2008).
16. DR Barnes, AC Antoniou: Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers. J Intern Med 271(4):331-343 (2012).
17. Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310-1316. (1999).
18. AC Antoniou, AB Spurdle, OM Sinilnikova, SHealey, KA Pooley, RK Schmutzler, B Versmold, C Engel, A Meindl, N Arnold, W Hofmann, C Sutter, D Niederacher, H Deissler, T Caldes, K Kampjarvi, H Nevanlinna, J Simard, J Beesley, X Chen, Kathleen Cuningham Consortium for Research into Familial Breast Cancer, SL Neuhausen, TR Rebbeck, T Wagner, HT Lynch, C Isaacs, J Weitzel, PA Ganz, MB Daly, G Tomlinson, OI Olopade, JL Blum, FJ Couch, P Peterlongo, S Manoukian, M Barile, P Radice, CI Szabo, LH Pereira, MH Greene, G Rennert, F Lejbkowicz, O Barnett-Griness, IL Andrulis, H Ozcelik, OCGN, AM Gerdes, MA Caligo, Y Laitman, B Kaufman, R Milgrom, E Friedman, Swedish BRCA1 and BRCA2 study collaborators, SM Domchek, KL Nathanson, A Osorio, G Llort, RL Milne, J Benitez, U Hamann, FB Hogervorst, P Manders, MJ Ligtenberg, AM van den Ouweland, DNA-HEBON collaborators, S Peock, M Cook, R Platte, DG Evans, R Eeles, G Pichert, C Chu, D Eccles, R Davidson, F Douglas, EMBRACE, AK Godwin, L Barjhoux, S Mazoyer, H Sobol, V Bourdon, F Eisinger, A Chompret, C Capoulade, B Bressac-de Paillerets, GM Lenoir, M Gauthier-Villars, C Houdayer, D Stoppa-Lyonnet, GEMO, G Chenevix-Trench, DF Easton and CIMBA: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 82, 937-948 (2008).
19. TR Rebbeck, N Mitra, SM Domchek, F Wan, TM Friebel, TV Tran, CF Singer, MK Tea, JL Blum, N Tung, OI Olopade, JN Weitzel, HT Lynch, CL Snyder, JE Garber, AC Antoniou, S Peock, DG Evans, J Paterson, MJ Kennedy, A Donaldson, H Dorkins, DF Easton, Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), WS Rubinstein, MB Daly, C Isaacs, H Nevanlinna, FJ Couch, IL Andrulis, E Freidman, Y Laitman, PA Ganz, GE Tomlinson, SL Neuhausen, SA Narod, CM Phelan, R Greenberg and KL Nathanson: Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res 71, 5792-5805 (2011).
20. G Bougeard, R Sesboue, S Baert-Desurmont, S Vasseur, C Martin, J Tinat, L Brugieres, A Chompret, BB de Paillerets, D Stoppa-Lyonnet, C Bonaiti-Pellie, T Frebourg and French LFS working group: Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45, 535-538 (2008).
21. A Blanco, B Grana, L Fachal, M Santamarina, J Cameselle-Teijeiro, C Ruiz-Ponte, A Carracedo and A Vega: Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN. Clin Genet 77, 193-196 (2010).
22. F Lalloo and DG Evans: Familial breast cancer. Clin Genet 82, 105-114 (2012).
23. AK Win, JP Young, NM Lindor, KM Tucker, DJ Ahnen, GP Young, DD Buchanan, M Clendenning, GG Giles, I Winship, FA Macrae, J Goldblatt, MC Southey, J Arnold, SN Thibodeau, SR Gunawardena, B Bapat, JA Baron, G Casey, S Gallinger, L Le Marchand, PA Newcomb, RW Haile, JL Hopper and MA Jenkins: Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30, 958-964 (2012).
24. T Walsh and MC King: Ten genes for inherited breast cancer. Cancer Cell 11, 103-105 (2007). (Pubitemid 46209856)
25. PD Pharoah, AC Antoniou, DF Easton and BA Ponder: Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358, 2796-2803 (2008). (Pubitemid 351930854)
26. DW Bell, JM Varley, TE Szydlo, DH Kang, DC Wahrer, KE Shannon, M Lubratovich, SJ Verselis, KJ Isselbacher, JF Fraumeni, JM Birch, FP Li, JE Garber and DA Haber: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528-2531 (1999).
27. L Antoni, N Sodha, I Collins and MD Garrett: CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 7, 925-936 (2007). (Pubitemid 350165855)
28. CHEK2 Breast Cancer Case-Control Consortium, CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10, 860 breast cancer cases and 9, 065 controls from 10 studies. Am J Hum Genet 74, 1175-1182 (2004).
29. M Weischer, SE Bojesen, C Ellervik, A Tybjaerg-Hansen and BG Nordestgaard: CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls. J Clin Oncol 26, 542-548 (2008). (Pubitemid 351264346)
30. L Fachal, M Santamarina, A Blanco, A Carracedo and A Vega: CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families. Clin Transl Oncol (2012).
31. MA Adank, MA Jonker, I Kluijt, SE van Mil, RA Oldenburg, WJ Mooi, FB Hogervorst, AM van den Ouweland, JJ Gille, MK Schmidt, AW van der Vaart, H Meijers-Heijboer and Q Waisfisz: CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet 48, 860-863 (2011).
32. T Walsh, S Casadei, KH Coats, E Swisher, SM Stray, J Higgins, KC Roach, J Mandell, MK Lee, S Ciernikova, L Foretova, P Soucek and MC King: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295, 1379-1388 (2006).
33. P Athma, R Rappaport and M Swift: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92, 130-134 (1996). (Pubitemid 26427675)
34. AJ Hartlerode and R Scully: Mechanisms of doublestrand break repair in somatic mammalian cells. Biochem J 423, 157-168 (2009).
35. M Swift, CL Chase, D Morrell: Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 46 (1), 21-27 (1990). (Pubitemid 20164925)
36. LL Paglia, A Lauge, J Weber, J Champ, E Cavaciuti, A Russo, JL Viovy and D Stoppa-Lyonnet: ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy. Breast Cancer Res Treat 119, 443-452 (2010).
37. A Renwick, D Thompson, S Seal, P Kelly, T Chagtai, M Ahmed, B North, H Jayatilake, R Barfoot, K Spanova, L McGuffog, DG Evans, D Eccles, Breast Cancer Susceptibility Collaboration (UK), DF Easton, MR Stratton and N Rahman: ATM mutations that cause ataxiatelangiectasia are breast cancer susceptibility alleles. Nat Genet 38, 873-875 (2006). (Pubitemid 44141653)
38. A Broeks, LM Braaf, A Huseinovic, MK Schmidt, NS Russell, FE van Leeuwen, FB Hogervorst and LJ Van 't Veer: The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat 107, 243-248 (2008). (Pubitemid 350265692)
39. MF Lavin: ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene 26, 7749-7758 (2007). (Pubitemid 350242462)
40. K Heikkinen, SM Karppinen, Y Soini, M Makinen and R Winqvist: Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J Med Genet 40, e131 (2003).
41. K Heikkinen, K Rapakko, SM Karppinen, H Erkko, S Knuutila, T Lundan, A Mannermaa, AL Borresen-Dale, A Borg, RB Barkardottir, J Petrini and R Winqvist: RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27, 1593-1599 (2006). (Pubitemid 44288048)
42. M Digweed and K Sperling: Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 3, 1207-1217 (2004). (Pubitemid 38997964)
43. N Bogdanova, S Feshchenko, P Schurmann, R Waltes, B Wieland, P Hillemanns, YI Rogov, O Dammann, M Bremer, JH Karstens, C Sohn, R Varon and T Dork: Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer 122, 802-806 (2008).
44. B Gorski, T Debniak, B Masojc, M Mierzejewski, K Medrek, C Cybulski, A Jakubowska, G Kurzawski, M Chosia, R Scott and J Lubinski: Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 106, 379-381 (2003). (Pubitemid 36870400)
45. N G Howlett, T Taniguchi, S Olson, B Cox, Q Waisfisz, C De Die-Smulders, N Persky, M Grompe, H Joenje, G Pals, H Ikeda, E A Fox and A D D'Andrea: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609 (2002). (Pubitemid 34815345)
46. G L Moldovan and A D D'Andrea: How the fanconi anemia pathway guards the genome. Annu Rev Genet 43, 223-249 (2009).
47. W Wang: Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8, 735-748 (2007). (Pubitemid 47429206)
48. D I Kutler, B Singh, J Satagopan, S D Batish, M Berwick, P F Giampietro, H Hanenberg and A D Auerbach: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101, 1249-1256 (2003). (Pubitemid 36182492)
49. O Levran, C Attwooll, R T Henry, K L Milton, K Neveling, P Rio, S D Batish, R Kalb, E Velleuer, S Barral, J Ott, J Petrini, D Schindler, H Hanenberg and A D Auerbach: The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37, 931-933 (2005). (Pubitemid 43086147)
50. S Cantor, R Drapkin, F Zhang, Y Lin, J Han, S Pamidi and DM Livingston: The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A 101, 2357-2362 (2004). (Pubitemid 38269316)
51. S Seal, D Thompson, A Renwick, A Elliott, P Kelly, R Barfoot, T Chagtai, H Jayatilake, M Ahmed, K Spanova, B North, L McGuffog, DG Evans, D Eccles, Breast Cancer Susceptibility Collaboration (UK), DF Easton, MR Stratton and N Rahman: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38, 1239-1241 (2006). (Pubitemid 44646283)
52. B Xia, JC Dorsman, N Ameziane, Y de Vries, MA Rooimans, Q Sheng, G Pals, A Errami, E Gluckman, J Llera, W Wang, D M Livingston, H Joenje and JP de Winter: Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39, 159-161 (2007). (Pubitemid 46184344)
53. N Rahman, S Seal, D Thompson, P Kelly, A Renwick, A Elliott, S Reid, K Spanova, R Barfoot, T Chagtai, H Jayatilake, L McGuffog, S Hanks, DG Evans, D Eccles, Breast Cancer Susceptibility Collaboration (UK), DF Easton and MR Stratton: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39, 165-167 (2007). (Pubitemid 46184346)
54. F Zhang, J Ma, J Wu, L Ye, H Cai, B Xia and X Yu: PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 19, 524-529 (2009).
55. H Erkko, JG Dowty, J Nikkila, K Syrjakoski, A Mannermaa, K Pylkas, MC Southey, K Holli, A Kallioniemi, A Jukkola-Vuorinen, V Kataja, VM Kosma, B Xia, DM Livingston, R Winqvist and JL Hopper: Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 14, 4667-4671 (2008).
56. S Jones, RH Hruban, M Kamiyama, M Borges, X Zhang, DW Parsons, JC Lin, E Palmisano, K Brune, EM Jaffee, CA Iacobuzio-Donahue, A Maitra, G Parmigiani, SE Kern, VE Velculescu, KW Kinzler, B Vogelstein, JR Eshleman, M Goggins and AP Klein: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).
57. C Stoepker, K Hain, B Schuster, Y Hilhorst-Hofstee, MA Rooimans, J Steltenpool, AB Oostra, K Eirich, ET Korthof, AW Nieuwint, NG Jaspers, T Bettecken, H Joenje, D Schindler, J Rouse and JP de Winter: SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 43, 138-141 (2011).
58. JL Bakker, SE van Mil, G Crossan, N Sabbaghian, K De Leeneer, B Poppe, M Adank, H Gille, H Verheul, H Meijers-Heijboer, JP de Winter, K Claes, M Tischkowitz and Q Waisfisz: Analysis of the Novel Fanconi Anemia Gene SLX4/FANCP in Familial Breast Cancer Cases. Hum Mutat (2012).
59. GR de Garibay, A Díaz, B Gaviña, A Romero, P Garre, A Vega, A Blanco, A Tosar, O Díez, P Pérez-Segura, E Díaz-Rubio, T Caldés, M de la Hoya Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families. Eur J Hum Genet (2012).
60. ER Thompson, MA Doyle, GL Ryland, SM Rowley, DY Choong, RW Tothill, H Thorne, kConFab, DR Barnes, J Li, J Ellul, GK Philip, YC Antill, PA James, AH Trainer, G Mitchell and IG Campbell: Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles. PLoS Genet 8, e1002894 (2012).
61. J Thacker: The RAD51 gene family, genetic instability and cancer. Cancer Lett 219, 125-135 (2005). (Pubitemid 40269475)
62. L Pellegrini, DS Yu, T Lo, S Anand, M Lee, TL Blundell and AR Venkitaraman: Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420, 287-293 (2002). (Pubitemid 35398178)
63. F Vaz, H Hanenberg, B Schuster, K Barker, C Wiek, V Erven, K Neveling, D Endt, I Kesterton, F Autore, F Fraternali, M Freund, L Hartmann, D Grimwade, R G Roberts, H Schaal, S Mohammed, N Rahman, D Schindler and C G Mathew: Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42, 406-409 (2010).
64. A Meindl, H Hellebrand, C Wiek, V Erven, B Wappenschmidt, D Niederacher, M Freund, P Lichtner, L Hartmann, H Schaal, J Ramser, E Honisch, C Kubisch, H E Wichmann, K Kast, H Deissler, C Engel, B Muller-Myhsok, K Neveling, M Kiechle, C G Mathew, D Schindler, R K Schmutzler and H Hanenberg: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42, 410-414 (2010).
65. A Osorio, D Endt, F Fernández, K Eirich, M de la Hoya, R Schmutzler, T Caldés, A Meindl, D Schindler, J Benitez: Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mol Genet 21(13):2889-2898 (2012).
66. C Loveday, C Turnbull, E Ramsay, D Hughes, E Ruark, JR Frankum, G Bowden, B Kalmyrzaev, M Warren-Perry, K Snape, JW Adlard, J Barwell, J Berg, AF Brady, C Brewer, G Brice, C Chapman, J Cook, R Davidson, A Donaldson, F Douglas, L Greenhalgh, A Henderson, L Izatt, A Kumar, F Lalloo, Z Miedzybrodzka, PJ Morrison, J Paterson, M Porteous, MT Rogers, S Shanley, L Walker, Breast Cancer Susceptibility Collaboration (UK), D Eccles, DG Evans, A Renwick, S Seal, CJ Lord, A Ashworth, JS Reis-Filho, AC Antoniou and N Rahman: Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43, 879-882 (2011).
67. N Liu, JE Lamerdin, RS Tebbs, D Schild, JD Tucker, MR Shen, KW Brookman, MJ Siciliano, CA Walter, W Fan, LS Narayana, ZQ Zhou, AW Adamson, KJ Sorensen, DJ Chen, NJ Jones and LH Thompson: XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1, 783-793 (1998). (Pubitemid 128379063)
68. M Garcia-Closas, KM Egan, PA Newcomb, LA Brinton, L Titus-Ernstoff, S Chanock, R Welch, J Lissowska, B Peplonska, N Szeszenia-Dabrowska, W Zatonski, A Bardin-Mikolajczak and JP Struewing: Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and metaanalyses. Hum Genet 119, 376-388 (2006).
69. A Auranen, H Song, C Waterfall, RA Dicioccio, B Kuschel, SK Kjaer, E Hogdall, C Hogdall, J Stratton, AS Whittemore, DF Easton, BA Ponder, KL Novik, AM Dunning, S Gayther and PD Pharoah: Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 117, 611-618 (2005). (Pubitemid 41504549)
70. SL Winsey, NA Haldar, HP Marsh, M Bunce, SE Marshall, AL Harris, F Wojnarowska and KI Welsh: A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 60, 5612-5616 (2000).
71. EM Sturgis, C Zhao, R Zheng and Q Wei: Radiation response genotype and risk of differentiated thyroid cancer: a case-control analysis. Laryngoscope 115, 938-945 (2005). (Pubitemid 40776979)
72. A Vral, P Willems, K Claes, B Poppe, G Perletti and H Thierens: Combined effect of polymorphisms in Rad51 and Xrcc3 on breast cancer risk and chromosomal radiosensitivity. Mol Med Report 4, 901-912 (2011).
73. HE Shamseldin, M Elfaki and FS Alkuraya: Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation. J Med Genet 49, 184-186 (2012).
74. LB Gao, XM Pan, LJ Li, WB Liang, Y Zhu, LS Zhang, YG Wei, M Tang and L Zhang: RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 125, 827-835 (2011).
75. DJ Park, F Lesueur, T Nguyen-Dumont, M Pertesi, F Odefrey, F Hammet, SL Neuhausen, EM John, IL Andrulis, MB Terry, M Daly, S Buys, F Le Calvez-Kelm, A Lonie, BJ Pope, H Tsimiklis, C Voegele, FM Hilbers, N Hoogerbrugge, A Barroso, A Osorio, Breast Cancer Family Registry, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, GG Giles, P Devilee, J Benitez, JL Hopper, SV Tavtigian, DE Goldgar and MC Southey: Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 90, 734-739 (2012).
76. M Saadat and M Ansari-Lari: Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat 115, 137-144 (2009).
77. H Kaneko and N Kondo: Clinical features of Bloom syndrome and function of the causative gene, BLM helicase. Expert Rev Mol Diagn 4, 393-401 (2004). (Pubitemid 38684714)
78. AP Sokolenko, AG Iyevleva, EV Preobrazhenskaya, NV Mitiushkina, SN Abysheva, EN Suspitsin, ES Kuligina, TV Gorodnova, W Pfeifer, AV Togo, EA Turkevich, AO Ivantsov, DV Voskresenskiy, GD Dolmatov, EM Bit-Sava, DE Matsko, V F Semiglazov, I Fichtner, AA Larionov, SG Kuznetsov, AC Antoniou and EN Imyanitov: High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Int J Cancer 130, 2867-2873 (2012).
79. SB Gruber, NA Ellis, KK Scott, R Almog, P Kolachana, JD Bonner, T Kirchhoff, LP Tomsho, K Nafa, H Pierce, M Low, J Satagopan, H Rennert, H Huang, JK Greenson, J Groden, B Rapaport, J Shia, S Johnson, PK Gregersen, CC Harris, J Boyd, G Rennert and K Offit: BLM heterozygosity and the risk of colorectal cancer. Science 297, 2013 (2002).
80. SP Cleary, W Zhang, N Di Nicola, M Aronson, J Aube, A Steinman, R Haddad, M Redston, S Gallinger, SA Narod and R Gryfe: Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res 63, 1769-1771 (2003). (Pubitemid 36460835)
81. B Wang, S Matsuoka, BA Ballif, D Zhang, A Smogorzewska, SP Gygi and SJ Elledge: Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316, 1194-1198 (2007). (Pubitemid 46877482)
82. B Wang, K Hurov, K Hofmann and SJ Elledge: NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev 23, 729-739 (2009).
83. L Feng, J Huang and J Chen: MERIT40 facilitates BRCA1 localization and DNA damage repair. Genes Dev 23, 719-728 (2009).
84. A Osorio, A Barroso, MJ Garcia, B Martinez-Delgado, M Urioste and J Benitez: Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility. Breast Cancer Res Treat 113, 371-376 (2009).
85. J Nikkila, KA Coleman, D Morrissey, K Pylkas, H Erkko, TE Messick, SM Karppinen, A Amelina, R Winqvist and RA Greenberg: Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function. Oncogene 28, 1843-1852 (2009).
86. S Solyom, J Patterson-Fortin, K Pylkas, RA Greenberg and R Winqvist: Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families. Breast Cancer Res Treat 120, 165-168 (2010).
87. NK Kolas, JR Chapman, S Nakada, J Ylanko, R Chahwan, FD Sweeney, S Panier, M Mendez, J Wildenhain, TM Thomson, L Pelletier, SP Jackson and D Durocher: Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 318, 1637-1640 (2007). (Pubitemid 350233664)
88. M Vuorela, K Pylkas and R Winqvist: Mutation screening of the RNF8, UBC13 and MMS2 genes in Northern Finnish breast cancer families. BMC Med Genet 12, 98 (2011).
89. L Li, MJ Halaby, A Hakem, R Cardoso, S El Ghamrasni, S Harding, N Chan, R Bristow, O Sanchez, D Durocher and R Hakem: Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. J Exp Med 207, 983-997 (2010).
90. GS Stewart, S Panier, K Townsend, AK Al-Hakim, NK Kolas, ES Miller, S Nakada, J Ylanko, S Olivarius, M Mendez, C Oldreive, J Wildenhain, A Tagliaferro, L Pelletier, N Taubenheim, A Durandy, PJ Byrd, T Stankovic, AM Taylor and D Durocher: The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 136, 420-434 (2009).
91. M Ghoussaini, O Fletcher, K Michailidou, C Turnbull, MK Schmidt, E Dicks, J Dennis, Q Wang, MK Humphreys, C Luccarini, C Baynes, D Conroy, M Maranian, S Ahmed, K Driver, N Johnson, N Orr, I dos Santos Silva, Q Waisfisz, H Meijers-Heijboer, AG Uitterlinden, F Rivadeneira, Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer (HEBON), P Hall, K Czene, A Irwanto, J Liu, H Nevanlinna, K Aittomaki, C Blomqvist, A Meindl, RK Schmutzler, B Muller-Myhsok, P Lichtner, J Chang-Claude, R Hein, S Nickels, D Flesch-Janys, H Tsimiklis, E Makalic, D Schmidt, M Bui, JL Hopper, C Apicella, DJ Park, M Southey, DJ Hunter, SJ Chanock, A Broeks, S Verhoef, FB Hogervorst, PA Fasching, MP Lux, MW Beckmann, AB Ekici, E Sawyer, I Tomlinson, M Kerin, F Marme, A Schneeweiss, C Sohn, B Burwinkel, P Guenel, T Truong, E Cordina-Duverger, F Menegaux, SE Bojesen, BG Nordestgaard, SF Nielsen, H Flyger, RL Milne, MR Alonso, A Gonzalez-Neira, J Benitez, H Anton-Culver, A Ziogas, L Bernstein, CC Dur, H Brenner, H Muller, V Arndt, C Stegmaier, Familial Breast Cancer Study (FBCS), C Justenhoven, H Brauch, T Bruning, Gene Environment Interaction of Breast Cancer in Germany (GENICA) Network, Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44, 312-318 (2012).
92. C Dickson, B Spencer-Dene, C Dillon and V Fantl: Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res 2, 191-196 (2000). (Pubitemid 32223584)
93. DF Easton, KA Pooley, AM Dunning, PD Pharoah, D Thompson, DG Ballinger, JP Struewing, J Morrison, H Field, R Luben, N Wareham, S Ahmed, CS Healey, R Bowman, KB Meyer, CA Haiman, LK Kolonel, BE Henderson, L Le Marchand, P Brennan, S Sangrajrang, V Gaborieau, F Odefrey, CY Shen, PE Wu, HC Wang, D Eccles, DG Evans, J Peto, O Fletcher, N Johnson, S Seal, MR Stratton, N Rahman, G Chenevix-Trench, SE Bojesen, BG Nordestgaard, CK Axelsson, M Garcia-Closas, L Brinton, S Chanock, J Lissowska, B Peplonska, H Nevanlinna, R Fagerholm, H Eerola, D Kang, KY Yoo, DY Noh, SH Ahn, DJ Hunter, SE Hankinson, DG Cox, P Hall, S Wedren, J Liu, YL Low, N Bogdanova, P Schürmann, T Dörk, R A Tollenaar, CE Jacobi, P Devilee, JG Klijn, AJ Sigurdson, MM Doody, BH Alexander, J Zhang, A Cox, IW Brock, G MacPherson, MW Reed, FJ Couch, EL Goode, JE Olson, H Meijers-Heijboer, A van den Ouweland, A Uitterlinden, F Rivadeneira, RL Milne, G Ribas, A Gonzalez-Neira, J Benitez, JL Hopper, M McCredie, M Southey, GG Giles, C Schroen, C Justenhoven, H Brauch, U Hamann, YD Ko, AB Spurdle, J Beesley, X Chen, A Mannermaa, VM Kosma, V Kataja, J Hartikainen, NE Day, DR Cox, BA Ponder: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148): 1087-1093 (2007). (Pubitemid 47014426)
94. SN Stacey, A Manolescu, P Sulem, T Rafnar, J Gudmundsson, SA Gudjonsson, G Masson, M Jakobsdottir, S Thorlacius, A Helgason, KK Aben, LJ Strobbe, M Albers-Akkers, DW Swinkels, BE Henderson, LN Kolonel, L Le Marchand, E Millastre, R Andres, J Godino, MD Garcia-Prats, E Polo, A Tres, M Mouy, J Saemundsdottir, VM Backman, L Gudmundsson, K Kristjansson, J T Bergthorsson, J Kostic, M L Frigge, F Geller, D Gudbjartsson, H Sigurdsson, T Jonsdottir, J Hrafnkelsson, J Johannsson, T Sveinsson, G Myrdal, HN Grimsson, T Jonsson, S von Holst, B Werelius, S Margolin, A Lindblom, JI Mayordomo, CA Haiman, LA Kiemeney, OT Johannsson, JR Gulcher, U Thorsteinsdottir, A Kong and K Stefansson: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39, 865-869 (2007). (Pubitemid 47014497)
95. B Gold, T Kirchhoff, S Stefanov, J Lautenberger, A Viale, J Garber, E Friedman, S Narod, AB Olshen, P Gregersen, K Kosarin, A Olsh, J Bergeron, NA Ellis, RJ Klein, AG Clark, L Norton, M Dean, J Boyd and K Offit: Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A 105, 4340-4345 (2008). (Pubitemid 351754382)
96. SN Stacey, A Manolescu, P Sulem, S Thorlacius, SA Gudjonsson, GF Jonsson, M Jakobsdottir, JT Bergthorsson, J Gudmundsson, KK Aben, LJ Strobbe, DW Swinkels, KC van Engelenburg, BE Henderson, LN Kolonel, L Le Marchand, E Millastre, R Andres, B Saez, J Lambea, J Godino, E Polo, A Tres, S Picelli, J Rantala, S Margolin, T Jonsson, H Sigurdsson, T Jonsdottir, J Hrafnkelsson, J Johannsson, T Sveinsson, G Myrdal, HN Grimsson, SG Sveinsdottir, K Alexiusdottir, J Saemundsdottir, A Sigurdsson, J Kostic, L Gudmundsson, K Kristjansson, G Masson, JD Fackenthal, C Adebamowo, T Ogundiran, OI Olopade, CA Haiman, A Lindblom, JI Mayordomo, LA Kiemeney, JR Gulcher, T Rafnar, U Thorsteinsdottir, OT Johannsson, A Kong and K Stefansson: Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40, 703-706 (2008). (Pubitemid 351748861)
97. M Garcia-Closas, P Hall, H Nevanlinna, K Pooley, J Morrison, DA Richesson, SE Bojesen, BG Nordestgaard, CK Axelsson, JI Arias, RL Milne, G Ribas, A Gonzalez-Neira, J Benitez, P Zamora, H Brauch, C Justenhoven, U Hamann, YD Ko, T Bruening, S Haas, T Dork, P Schurmann, P Hillemanns, N Bogdanova, M Bremer, JH Karstens, R Fagerholm, K Aaltonen, K Aittomaki, K von Smitten, C Blomqvist, A Mannermaa, M Uusitupa, M Eskelinen, M Tengstrom, VM Kosma, V Kataja, G Chenevix-Trench, AB Spurdle, J Beesley, X Chen, Australian Ovarian Cancer Management Group, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, P Devilee, CJ van Asperen, CEJacobi, RA Tollenaar, PE Huijts, JG Klijn, J Chang-Claude, S Kropp, T Slanger, D Flesch-Janys, E Mutschelknauss, R Salazar, S Wang-Gohrke, F Couch, EL Goode, JE Olson, C Vachon, Z S Fredericksen, GG Giles, L Baglietto, G Severi, JL Hopper, DR English, MC Southey, CA Haiman, BE Henderson, LN Kolonel, L Le Marchand, DO Stram, DJ Hunter, SE Hankinson, DG Cox, R Tamimi, P Kraft, ME Sherman, S J Chanock, J Lissowska, L A Brinton, B Peplonska, J G Klijn, M J Hooning, H Meijers-Heijboer, J M Collee, A van den Ouweland, AG Uitterlinden, J Liu, LY Lin, L Yuqing, K Humphreys, K Czene, A Cox, SP Balasubramanian, SS Cross, MW Reed, F Blows, K Driver, A Dunning, J Tyrer, BA Ponder, S Sangrajrang, P Brennan, J McKay, F Odefrey, V Gabrieau, A Sigurdson, M Doody, JP Struewing, B Alexander, DF Easton and PD Pharoah: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4, e1000054 (2008).
98. SM Domchek, TM Friebel, CF Singer, DG Evans, HT Lynch, C Isaacs, JE Garber, SL Neuhausen, E Matloff, R Eeles, G Pichert, L Van t'veer, N Tung, J N Weitzel, FJ Couch, WS Rubinstein, PA Ganz, MB Daly, OI Olopade, G Tomlinson, J Schildkraut, JL Blum and TR Rebbeck: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304, 967-975 (2010).
99. AC Antoniou, PD Pharoah, G McMullan, NE Day, MR Stratton, J Peto, BJ Ponder and DF Easton: A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86, 76-83 (2002). (Pubitemid 34146344)
100. T Walsh, S Casadei, MK Lee, CC Pennil, AS Nord, AM Thornton, W Roeb, KJ Agnew, SM Stray, A Wickramanayake, B Norquist, KP Pennington, RL Garcia, MC King and EM Swisher: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108, 18032-18037 (2011).